Robin Kroll
University of Washington
11 Papers
12 Citations
Robin Kroll is an academic researcher from University of Washington. The author has contributed to research in topics: Medicine & Pearl Index. The author has an hindex of 4, co-authored 11 publications.
Chat about Author
Papers
Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden.
Rossella E. Nappi,Robin Kroll,Emad Siddiqui,Boyka Stoykova,Carol Rea,Eric Gemmen,Neil M. Schultz +6 more
TL;DR: In this paper, the prevalence and health-related quality of life (HRQOL) of moderate-to-severe vasomotor symptoms (VMS) in postmenopausal women in Europe, the US, and Japan, and among subgroups of women not taking hormone therapy (HT) were determined.
115
Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults
Anuradha Madan,Nathan Segall,Murdo Ferguson,Louise Frenette,Robin Kroll,Damien Friel,Jyoti Soni,Ping Li,Bruce L. Innis,Anne Schuind +9 more
TL;DR: Two doses of AS03-adjuvanted H7N9 vaccine were well tolerated and induced a robust antibody response at antigen-sparing doses in healthy adults and met regulatory acceptance criteria.
42
Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results.
Anita L. Nelson,Andrew M. Kaunitz,Robin Kroll,James A. Simon,Alfred N. Poindexter,Paula M. Castaño,Ronald T. Ackerman,Lisa Flood,Joseph Chiodo,Elizabeth I.O. Garner +9 more
TL;DR: Results of this phase 3 study supported the FDA approval of TWIRLA® for prevention of pregnancy in women with BMI <30 kg/m2 and the TDS safety and tolerability profile was consistent with other similar dose combined hormonal contraceptives.
22
Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
TL;DR: In the REPLENISH trial, women with moderate to severe VMS treated with most E2/P4 doses reported significant improvements in quality of life from baseline to 12 weeks compared with placebo, which were maintained up to 12 months.
20
Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial
TL;DR: Ovarian activity suppression of a 21/7-active low-dose combined oral contraceptive (COC) regimen that included only ethinyl estradiol (EE) during the traditional hormone-free interval (HFI) showed suppression of ovarian follicular activity that was similar to the 24/4 (DRSP/EE+4days PBO) and the 21/ 7 (LNG/EE-7 days P BO) comparator regimens.
15